TrialsgrambetaRCTs are beautiful
AHA Scientific Sessions 2026Presentato lun 9 nov · 09:55 GMT-6LBS.06 Late-breaking Science: Artificial Intelligence in the Diagnosis of Cardiovascular DiseaseTutti gli studi Late-Breaking Science →

WATCH-LV

2026

Consumer Smartwatch Artificial Intelligence-Enabled Electrocardiogram for Left Ventricular Systolic Dysfunction: Cross-Manufacturer Validation and Serial Home Monitoring (WATCH-LV)

In adults referred for echocardiography, an AI model reading single-lead smartwatch ECGs distinguished people with and without left ventricular systolic dysfunction about equally well on two brands of watch, although 9% of results disagreed between devices.

Risultato

Endpoint primario: Diagnostic performance for left ventricular systolic dysfunction

The AI model distinguished people with and without LVSD about equally well on both watches. At the same AI-score cutoff, 200 participants (9%) were classified as positive on one watch and negative on the other. In the home monitoring cohort, requiring at least 2 of 3 consecutive positive recording days reduced false-positive classifications from 18 to 9 among the 70 participants without LVSD, and identified 31 of 38 participants with LVSD compared with 33 using single-positive days. 81% of those with consistently positive results had LVSD confirmed by echocardiography vs about 6% of those with consistently negative results. Nearly half (49%) had mixed results, and 40% of this group had confirmed LVSD.

Pubblicazione originale
Sottotema
Heart failure & cardiomyopathy
Disegno
Validation study of an AI algorithm reading single-lead consumer-smartwatch ECGs from several manufacturers for left ventricular systolic dysfunction, with serial home recordings
Arruolati
2211 pazienti
Fonte
Lee HS. Presented at AHA Scientific Sessions 2026, 9 November. American Heart Association newsroom, late-breaking abstract 27869. Not yet published.

Discussione e critica

This single-centre study suggests an AI model can flag left ventricular systolic dysfunction from single-lead smartwatch ECGs on two manufacturers' devices, but 9% of participants got discordant results between watches. The release reports no area under the curve, sensitivity or specificity for the clinic cohort, and the population was referred for echocardiography, so performance in an unselected screening population is unknown. The serial home monitoring analysis included only 108 participants and is exploratory: poor-quality recordings were excluded and participants were reminded to record. The study did not test whether acting on the results leads to earlier treatment or better clinical outcomes, and the abstract has not been peer reviewed.